VC-backed public offerings at lowest ebb since 2011

Ben Adams Six venture-backed IPOs raised just $ 574.5 million in the first quarter of 2016, according to the Exit Poll Report, marking the slowest quarter for these types of offerings ...

Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand Plenty of Bayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, ...

FDA leaves biosim trial data off product labels in new guidance

Carly Helfand The FDA is out with new guidance for labeling biosimilar drugs–and it may not make some drugmakers happy. Regulators dismissed pharma's request that ...

GSK wins European regulator nod for new gene therapy

Ben Adams GlaxoSmithKline has won a key recommendation from the European regulator the EMA today for Strimvelis–a groundbreaking new gene therapy for children living with an incredibly ...
Page 2 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS